GSK (LON:GSK) Receives Equal Weight Rating from Barclays

GSK (LON:GSK)‘s stock had its “equal weight” rating restated by Barclays in a research report issued on Tuesday, Digital Look reports. They presently have a GBX 1,725 ($21.67) price target on the stock. Barclays‘s price target points to a potential downside of 1.82% from the stock’s current price.

A number of other research firms have also commented on GSK. JPMorgan Chase & Co. raised their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the company an “underweight” rating in a research note on Thursday, May 2nd. Berenberg Bank lifted their price target on GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($24.50) price objective on shares of GSK in a report on Wednesday, April 17th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.05).

GSK Price Performance

GSK stock traded up GBX 23.50 ($0.30) during trading on Tuesday, hitting GBX 1,757 ($22.07). The company had a trading volume of 114,133,024 shares, compared to its average volume of 8,060,302. The business has a 50 day moving average of GBX 1,664.46 and a 200 day moving average of GBX 1,560.76. The firm has a market capitalization of £71.86 billion, a price-to-earnings ratio of 1,466.25, a P/E/G ratio of 1.12 and a beta of 0.27. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82. GSK has a fifty-two week low of GBX 1,302.60 ($16.36) and a fifty-two week high of GBX 1,767.50 ($22.20).

Insider Transactions at GSK

In related news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,747.94). In other news, insider Urs Rohner purchased 434 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were purchased at an average cost of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,061.66). Also, insider Emma Walmsley sold 139,792 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,747.94). 1.77% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.